These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 34497607)

  • 21. IgG4 Autoantibodies Attenuate Systemic Lupus Erythematosus Progression by Suppressing Complement Consumption and Inflammatory Cytokine Production.
    Pan Q; Xiao H; Shi L; He Y; Cai J; Wu J; Li A; Ye L; Yang C; Liu HF
    Front Immunol; 2020; 11():1047. PubMed ID: 32625200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deficient leptin signaling ameliorates systemic lupus erythematosus lesions in MRL/Mp-Fas lpr mice.
    Fujita Y; Fujii T; Mimori T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Tanaka M; Masaki Y; Fukushima T; Okazaki T; Umehara H
    J Immunol; 2014 Feb; 192(3):979-84. PubMed ID: 24391210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells.
    Arnold R; Vehns E; Randl H; Djabali K
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW
    Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baricitinib: From Rheumatoid Arthritis to COVID-19.
    Assadiasl S; Fatahi Y; Mosharmovahed B; Mohebbi B; Nicknam MH
    J Clin Pharmacol; 2021 Oct; 61(10):1274-1285. PubMed ID: 33870531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ophiopogonin D attenuates the progression of murine systemic lupus erythematosus by reducing B cell numbers.
    Nie Y; Li C; Sun N
    J Biochem Mol Toxicol; 2023 Jul; 37(7):e23361. PubMed ID: 36999444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids.
    Nystrom SE; Li G; Datta S; Soldano KL; Silas D; Weins A; Hall G; Thomas DB; Olabisi OA
    JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35472001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety of baricitinib in patients with rheumatoid arthritis.
    Honda S; Harigai M
    Expert Opin Drug Saf; 2020 May; 19(5):545-551. PubMed ID: 32174196
    [No Abstract]   [Full Text] [Related]  

  • 29. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.
    Kim S; Ruminski P; Singh M; Staser K; Ashami K; Ritchey J; Lim S; DiPersio JF; Choi J
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
    Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
    Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of baricitinib for the treatment of systemic lupus erythematosus patients: A meta-analysis of randomized controlled trials.
    Panda AK; Ranjan S; Sahu JK
    Int J Rheum Dis; 2024 Jan; 27(1):e14964. PubMed ID: 37950554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
    Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
    Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pim-1 as a Therapeutic Target in Lupus Nephritis.
    Fu R; Xia Y; Li M; Mao R; Guo C; Zhou M; Tan H; Liu M; Wang S; Yang N; Zhao J
    Arthritis Rheumatol; 2019 Aug; 71(8):1308-1318. PubMed ID: 30791224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baricitinib protects ICIs-related myocarditis by targeting JAK1/STAT3 to regulate Macrophage polarization.
    Wang X; Chen J; Shen Y; Zhang H; Xu Y; Zhang J; Cheng L
    Cytokine; 2024 Jul; 179():156620. PubMed ID: 38701735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
    Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y
    Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice.
    Wang S; Yang N; Zhang L; Huang B; Tan H; Liang Y; Li Y; Yu X
    Lupus; 2010 Sep; 19(10):1171-80. PubMed ID: 20501525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex-specific differences in SLE - Significance in the experimental setting of inflammation and kidney damage in MRL-Fas
    Saurin S; Meineck M; Claßen P; Boedecker-Lips SC; Pautz A; Weinmann-Menke J
    Autoimmunity; 2024 Dec; 57(1):2377098. PubMed ID: 39004847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro.
    Murakami K; Kobayashi Y; Uehara S; Suzuki T; Koide M; Yamashita T; Nakamura M; Takahashi N; Kato H; Udagawa N; Nakamura Y
    PLoS One; 2017; 12(7):e0181126. PubMed ID: 28708884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
    Lu LD; Stump KL; Wallace NH; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Mason JL; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
    J Immunol; 2011 Oct; 187(7):3840-53. PubMed ID: 21880982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unraveling the podocyte injury in lupus nephritis: Clinical and experimental approaches.
    Dos Santos M; Poletti PT; Milhoransa P; Monticielo OA; Veronese FV
    Semin Arthritis Rheum; 2017 Apr; 46(5):632-641. PubMed ID: 27839739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.